Study Suggests Early Alzheimer’s Signs May Be Detectable by Age 45
Alzheimer’s disease is a progressive brain disorder that can begin decades before obvious symptoms appear. New research from New Zealand suggests that early biological signs of the condition may already be detectable by age 45. The findings raise the prospect of identifying at-risk adults long before dementia develops.
Scientists focused on a blood biomarker called pTau181, a phosphorylated form of the tau protein linked to Alzheimer’s pathology. In the study, levels of pTau181 were compared with participants’ self-reported memory and thinking difficulties in midlife. The work builds on growing evidence that subtle cognitive concerns can signal changes long before a formal diagnosis.
Clues from a 50-year cohort study
The research drew on the Dunedin Multidisciplinary Health and Development Study, a globally respected cohort study based at the University of Otago. This project has been tracking more than 1,000 people born in 1972–1973 in Dunedin, following their health and behavior for more than 50 years. It provides a rare, detailed view of brain health across the lifespan.
At age 45, participants provided blood samples and completed assessments of memory and thinking. They also reported whether they noticed everyday problems, such as forgetting names, losing track of conversations, or misplacing items. Researchers then examined whether higher pTau181 levels were associated with these self-reported cognitive concerns.
Biomarker tied to subjective memory issues
The study found that adults who expressed concerns about their memory or thinking tended to have higher levels of pTau181 in their blood. These subjective complaints were relatively mild and would not qualify as dementia. Yet they appeared to track with a biomarker strongly associated with Alzheimer’s disease in older patients.
Importantly, participants were still in midlife, decades younger than the typical age of dementia diagnosis, which often occurs in a person’s 70s or 80s. The authors suggest that combining blood biomarkers with self-reported cognitive concerns may help identify individuals on a higher-risk trajectory long before standard clinical tests reveal problems.
No clear changes on brain scans yet
Despite the biomarker association, the researchers did not find strong relationships between pTau181 levels and MRI measures of brain structure at age 45. Nor did higher pTau181 levels consistently predict poorer performance on detailed cognitive tests at that age. This discrepancy raises important questions about how Alzheimer’s disease develops during its earliest stages.
One possibility is that pTau181 begins to rise during a very early, preclinical phase of the disease. People may start noticing changes in their everyday memory at this point, even though structural brain scans and standard cognitive tests still appear normal. Another possibility is that elevated pTau181 in midlife reflects biological processes that only become clearly linked to Alzheimer’s disease later in life.
Why early detection matters
In recent years, new Alzheimer’s drugs targeting amyloid and tau have shown that they can modestly slow cognitive decline. However, these treatments do not cure the disease or restore lost function once extensive damage has occurred. Experts widely believe they will be most effective if started before major brain deterioration develops.
That makes early detection crucial. If clinicians can identify people at elevated risk in their 40s or 50s, there may be a larger window for intervention. These interventions could include lifestyle changes such as improving physical activity, diet, and sleep; maintaining social engagement; managing hypertension and diabetes; and addressing hearing loss, all of which have been linked to dementia risk.
Rethinking everyday forgetfulness
Many adults notice that their memory is not as sharp as it once was and assume this is simply a normal part of aging. In most cases, occasional lapses, such as misplacing keys or forgetting a word, are benign. However, research increasingly suggests that persistent subjective cognitive complaints can sometimes serve as an early warning sign.
Studies indicate that people often notice subtle declines in memory before formal cognitive tests detect a problem. The new Dunedin findings add weight to the idea that these self-reported concerns should not be dismissed, especially when paired with biological markers such as pTau181. Over time, such combinations may help distinguish between normal aging and emerging disease.
Next steps for long-term follow-up
The researchers caution that their work does not prove that every 45-year-old with elevated pTau181 and concerns about memory will develop Alzheimer’s disease. Long-term follow-up is essential to determine which individuals go on to develop brain changes, cognitive decline, or a clinical diagnosis. The Dunedin cohort will continue to be studied as participants move into their 50s and beyond.
Future research will also compare pTau181 with other blood biomarkers, including different tau fragments and amyloid-related proteins. Scientists aim to develop a more accurate risk profile that could one day be used in routine clinical practice. Any such tools will need to be carefully validated and combined with appropriate counseling to avoid unnecessary anxiety.
The new study underscores a broader shift in dementia research toward prevention and early intervention rather than waiting for severe symptoms to appear. By examining middle age more closely, scientists hope to identify the earliest biological and behavioral signals of disease. That, in turn, could open the door to targeted strategies that help protect brain health across the lifespan.
The article, authored by Ashleigh Barrett-Young of the University of Otago, was originally published by The Conversation and republished under a Creative Commons license. It contributes to a growing body of research exploring how blood tests and self-reported experiences could transform the way clinicians detect and manage Alzheimer’s disease in its earliest, most treatable stages.
